HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Sun Pharma to buy Organon for $11.75B in major portfolio expansion

Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021. The all-cash deal came in at $14 per share ...

By Endpoints News · Apr 27, 2026 · via Endpoints News
Sun Pharma to buy Organon for $11.75B in major portfolio expansion

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News

Tags
dealsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
DealsFiercePharma ↗
Merck & Co.’s $1 billion deal with Google Cloud is seeking to bolster its AI credentials—and the U.S. Big …
Apr 27, 2026
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
DealsFierceBiotech ↗
McKesson has let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo…
Apr 27, 2026
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
DealsFierceBiotech ↗
Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking t…
Apr 25, 2026